RCM
APLS

RA Capital Management’s Apellis Pharmaceuticals APLS Stock Holding History

RA Capital Management’s Portfolio APLS Stock Details APLS Fund Activity
Bought
Maintained
Sold
Quarter Market Value Status Shares Change in
Stake 		Trade Value Portfolio Weight Portfolio Position
2018
Q4 		– Sell
-900,000
Closed -$16M – 26
2018
Q3 		$16M Hold
900,000
– – 0.86% 23
2018
Q2 		$19.8M Hold
900,000
– – 1.29% 18
2018
Q1 		$19.9M Hold
900,000
– – 1.52% 16
2017
Q4 		$19.5M Buy
+900,000
New +$13.2M 1.63% 14

Other funds holding APLS

CAM
Cormorant Asset Management Boston, Massachusetts $1.99B AUM 737.95% 1-Year Est. Return
BlackRock
BlackRock New York $5.72T AUM 30.48% 1-Year Est. Return
HA
HHLR Advisors Grand Cayman, Cayman Islands $1.67B AUM 7.53% 1-Year Est. Return
SAM
Sectoral Asset Management Montreal, Quebec, Canada $121M AUM 73.47% 1-Year Est. Return
HIM
Hillhouse Investment Management Grand Cayman, Cayman Islands $3.13B AUM 7.29% 1-Year Est. Return
VP
venBio Partners San Francisco, California $281M AUM 261.03% 1-Year Est. Return
Vanguard Group
Vanguard Group Malvern, Pennsylvania $6.9T AUM 27.45% 1-Year Est. Return
Victory Capital Management
Victory Capital Management San Antonio, Texas $156B AUM 27.51% 1-Year Est. Return
Millennium Management
Millennium Management New York $240B AUM 35.51% 1-Year Est. Return
State Street
State Street Boston, Massachusetts $2.9T AUM 29.55% 1-Year Est. Return

RA Capital Management's APLS Position: Q4 2018 in Review

RA Capital Management sold out of Apellis Pharmaceuticals (APLS) in Q4 2018, closing a stake of 900,000 shares — an estimated $16M sold.

RA Capital Management first reported a position in APLS in Q4 2017 and held it in 4 quarters. The position peaked at $19.9M in Q1 2018. 95 funds tracked by Wall St. Rank hold APLS as of Q4 2018.

  • RA Capital Management reported no remaining Apellis Pharmaceuticals position as of Q4 2018 after selling out during the quarter.
  • RA Capital Management sold 900,000 Apellis Pharmaceuticals shares in Q4 2018, an estimated $16M.
  • RA Capital Management first reported a position in Apellis Pharmaceuticals in Q4 2017 and held it in 4 quarters.
  • RA Capital Management's Apellis Pharmaceuticals position peaked at $19.9M in Q1 2018.
  • 95 funds tracked by Wall St. Rank held Apellis Pharmaceuticals as of Q4 2018.

Based on RA Capital Management's 13F filing for Q4 2018, filed 14 Feb 2019.